Adaptimmune Therapeutics Plc Profit Margin

Adaptimmune Therapeutics Plc (ADAP) currently reports a profit margin of -260.82% as of June 2025. That compares with -51.44% in the prior-year period — down 407.1% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Adaptimmune Therapeutics Plc's profit margin history and peer comparisons.

Adaptimmune Therapeutics Plc's profit margin decreased from -51.44% to -260.82% — a 407.1% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adaptimmune Therapeutics Plc's profit margin of -260.82% is lower than the Healthcare sector average of 13.89%. That is roughly 1977.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Adaptimmune Therapeutics Plc's current -260.82% should be judged against Healthcare norms (sector average: 13.89%) and against ADAP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -260.82%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Adaptimmune Therapeutics Plc, and consider following ADAP for alerts when major investors trade the stock.